{"id":25998,"date":"2022-10-10T06:42:39","date_gmt":"2022-10-10T06:42:39","guid":{"rendered":"https:\/\/zeepedia.com\/?p=25998"},"modified":"2022-10-10T08:23:02","modified_gmt":"2022-10-10T08:23:02","slug":"umanbig","status":"publish","type":"post","link":"https:\/\/zeepedia.com\/medical\/medicines\/umanbig\/","title":{"rendered":"Umanbig &#8211; Immunoglobulin uses, dose and side effects"},"content":{"rendered":"\n<p>180 IU\/ml&nbsp;solution&nbsp;<\/p>\n\n\n\n<p>for injection<br>Human immune globulin against&nbsp;hepatitis&nbsp;B<a><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What Umanbig is and what it is used for<\/h2>\n\n\n\n<p>Umanbig is a solution of human immunoglobulin against&nbsp;hepatitis&nbsp;B. Immunoglobulins are blood proteins and act as&nbsp;antibodies&nbsp;.<\/p>\n\n\n\n<p>Umanbig is used in the following cases:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>to prevent re-infection with\u00a0hepatitis\u00a0B after liver transplantation due to liver failure caused by\u00a0hepatitis\u00a0B.<\/li><li>to quickly provide available\u00a0antibodies\u00a0against\u00a0the hepatitis\u00a0B\u00a0virus\u00a0to prevent\u00a0hepatitis\u00a0B in the following cases:<ul><li>in non-immunized persons (i.e. persons not vaccinated against\u00a0hepatitis\u00a0B\u00a0virus, including persons whose vaccination is incomplete or where information on vaccination is missing) who have been inadvertently exposed to\u00a0hepatitis\u00a0B\u00a0virus<\/li><li>in hemodialysis patients (i.e. people who have severe renal impairment and who require the blood to be purified artificially), until vaccination has been effective<\/li><li>in newborn children of mothers who are carriers of the\u00a0hepatitis\u00a0B\u00a0virus<\/li><li>in people who have not shown an\u00a0immune response\u00a0after vaccination (i.e. peoplein whom the vaccination has not been effective), and for whom regular preventive treatment is necessary due to the\u00a0continuous\u00a0risk of being infected with\u00a0hepatitis\u00a0B.<\/li><\/ul><\/li><\/ul>\n\n\n\n<p>Human&nbsp;hepatitis&nbsp;B immune globulin contained in Umanbig may also be approved to treat other diseases not mentioned in this product information.&nbsp;Ask your doctor, pharmacist or other healthcare professional if you have any further questions and always follow their instructions.<br><a><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What you need to know before using Umanbig<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Do not use Umanbig<\/h2>\n\n\n\n<p>if you are allergic to human immunoglobulins or any of the other ingredients of this medicine (listed in section 6).<\/p>\n\n\n\n<p>If you have a deficiency of immunoglobulin A (&nbsp;IgA&nbsp;), you can develop&nbsp;antibodies&nbsp;against immunoglobulin A in the blood.&nbsp;Umanbig contains small amounts of&nbsp;IgA&nbsp;and thus severe allergic reactions can occur.&nbsp;The doctor must therefore consider the benefits of treatment with Umanbig against the possible risk of allergic reactions<a><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Warnings and precautions<\/h2>\n\n\n\n<p>Talk to your doctor, pharmacist, or nurse before using Umanbig.<\/p>\n\n\n\n<p>The person giving Umanbig to you should ensure that the medicine is not given into a blood vessel.\u00a0This can produc,e ananother healthcare professionalof the circulatory system, known a,s\u00a0shock\u00a0.<\/p>\n\n\n\n<p>If you are a carrier of HBsAg, there is no benefit in using this medicine.<\/p>\n\n\n\n<p>Serious allergic reactions are rare.<\/p>\n\n\n\n<p>Human&nbsp;hepatitis&nbsp;B immunoglobulin can rarely cause a drop in blood pressure with respiratory effects, fainting, sometimes with fever and skin reactions (&nbsp;anaphylactic reaction&nbsp;).&nbsp;This can occur even if you have not had such a reaction during previous treatment with immunoglobulin.<\/p>\n\n\n\n<p>If the doctor or the person giving the medicine to you suspects an allergic or\u00a0anaphylactic reaction, the treatment should be stopped immediately.\u00a0If\u00a0shock\u00a0occurs, doctors should follow standard medical treatment for\u00a0shock.<\/p>\n\n\n\n<p>If you notice any of these symptoms;\u00a0breathing difficulties, pain in and swelling of the arms or legs, loss of movement or feeling in a body part (so-called focal neurological loss), and chest pain contact a doctor immediately or go to the nearest hospital, because you may have had a blood clot.<\/p>\n\n\n\n<p>This medicine contains 3.9 mg\u00a0of sodium\u00a0per ml.\u00a0This should be taken into account if you have been prescribed a low-salt diet, aand nd are dept on the total\u00a0dose of\u00a0a Umanbig.<\/p>\n\n\n\n<p>When medicines are made from&nbsp;human&nbsp;plasma&nbsp;or blood, special measures are taken to prevent&nbsp;infection&nbsp;from being passed on to patients.&nbsp;This includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>a careful selection of blood and plasma donors, to ensure that people at risk of being carriers are excluded<\/li><li>a sampling of donors to ensure that there are no infectious agents and\/or\u00a0viruses<\/li><li>measures to neutralize or remove\u00a0viruses\u00a0during manufacturing.<\/li><\/ul>\n\n\n\n<p>Despite this, the risk of transmission of\u00a0infection\u00a0cannot be completely excluded when medicines made from human blood or\u00a0plasma\u00a0are given.\u00a0This also applies to new, hitherto unknown\u00a0viruses\u00a0and other types of\u00a0infection.<\/p>\n\n\n\n<p>The measures taken are considered effective against enveloped\u00a0viruses, such as human immunodeficiency virus (\u00a0HIV\u00a0),\u00a0hepatitis\u00a0B\u00a0virus\u00a0(HBV),\u00a0hepatitis\u00a0C\u00a0virus\u00a0(\u00a0HCV\u00a0), and the non-enveloped\u00a0hepatitis\u00a0A\u00a0virus\u00a0et (HAV).<\/p>\n\n\n\n<p>The measures may be of limited value against&nbsp;viruses&nbsp;such as parvovirus B19.<\/p>\n\n\n\n<p>Immunoglobulins have not been able to be linked to&nbsp;infection&nbsp;with&nbsp;hepatitis&nbsp;A or parvovirus B19, probably due to the fact that the&nbsp;antibodies&nbsp;in the product have a protective effect.<\/p>\n\n\n\n<p>When given Umanbig, it is strongly recommended that the product name and batch number be recorded to enable the tracking of used product.<\/p>\n\n\n\n<p><em>Effect on blood samples<\/em><\/p>\n\n\n\n<p>If you have to give a blood test after receiving Umanbig, you must tell the nurse or doctor that you have received this medicine.\u00a0Umanbig can interfere with some tests for\u00a0antibodies\u00a0against\u00a0red blood cells.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Children<\/h2>\n\n\n\n<p>No special measures or special supervision are required for children.<a><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Other medicines and Umanbig<\/h2>\n\n\n\n<p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.<\/p>\n\n\n\n<p>Umanbig must not be mixed with other medicines.<\/p>\n\n\n\n<p><em>Live attenuated virus vaccines<\/em><\/p>\n\n\n\n<p>Umanbig can affect the development of the\u00a0immune response\u00a0to vaccines with live atbecauseh as rubella, mumps, measles, and chicken pox.\u00a0The use of immunoglobulin may affect the effectiveness of these vaccines for at least 3 months.\u00a0After\u00a0administration\u00a0of Umanbigthe , a period of at least 3 months should elapse before vaccination with live attenuated\u00a0virus\u00a0is performed.<\/p>\n\n\n\n<p>After vaccination with a live attenuated\u00a0virus, three to four weeks should elapse before human\u00a0hepatitis\u00a0B immunoglobulin is used.\u00a0If the use of human\u00a0hepatitis\u00a0B immunoglobulin is necessary within three to four weeks after vaccination, vaccination should be carried out again three months after the use of human\u00a0hepatitis\u00a0B immunoglobulin.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Pregnancy, breastfeeding, and fertility<\/h2>\n\n\n\n<p>If you are pregnant or breast-feeding, think you may be pregnant, or are planning to try to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<\/p>\n\n\n\n<p><strong>Pregnancy<\/strong><\/p>\n\n\n\n<p>The safety of this drug for use in pregnant women has not been established in controlled\u00a0clinical trials\u00a0and should therefore only be given with caution to pregnant women.\u00a0Clinical experience with immunoglobulins does not the indicate that any harmful effects during pregnancy, on the fetus or the newborn child can be expected.<\/p>\n\n\n\n<p><strong>Breast-feeding<\/strong><\/p>\n\n\n\n<p>The safety of Umanbig has not been established in controlled&nbsp;clinical trials&nbsp;and should therefore be given with caution to breastfeeding women.&nbsp;Immunoglobulins pass into breast milk and can help protect the newborn from&nbsp;pathogens&nbsp;that enter the body via mucous membranes.<\/p>\n\n\n\n<p><strong>Fertility<\/strong><\/p>\n\n\n\n<p>Clinical experience with immunoglobulibreastfeedingat no harmful effect on\u00a0fertility\u00a0is expected.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Driving ability and use of machinery<\/h2>\n\n\n\n<p>Umanbig has no or negligible effects on the ability to drive and use machines.&nbsp;If you experience&nbsp;side effects&nbsp;during the treatment, you must wait until these subside before driving or operating machinery.<\/p>\n\n\n\n<p><strong>Umanbig contains&nbsp;sodium<\/strong><\/p>\n\n\n\n<p>This medicinal product contains 3.9 mg and 11.7 mg of\u00a0sodium\u00a0(the main ingredient in common\/table salt) per\u00a01\u00a0ml and\u00a03 m,l\u00a0vial , respectively.\u00a0This corresponds to 0.19% and 0.58% respectively of the maximum recommended daily intake of\u00a0sodium\u00a0for adults.<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How to use Umanbig<\/h2>\n\n\n\n<p>Always take this medicine as directed by your doctor or pharmacist.&nbsp;Ask your doctor or pharmacist if you are unsure.<\/p>\n\n\n\n<p>Umanbig should be given as an\u00a0injection\u00a0into a muscle (\u00a0intramuscular\u00a0).\u00a0The medicine must be adjusted to room or body temperature before use.\u00a0Remove the outermost protection from the rubber stopper and draw up the solution into a\u00a0syringe.\u00a0Change the needle and inject.\u00a0Once the solution has been drawn up into the syringe, the medicine should be given immediately.<\/p>\n\n\n\n<p>The solution is clear and colorless or light yellow to light brown.\u00a0Do not use solution that is cloudy or contains particles.\u00a0If larger volumes (over 2 ml for children or over 5 ml for dults) are required, it is recommended that one\u00a0dose\u00a0be divided into several\u00a0doses\u00a0and given at different injection sites.<\/p>\n\n\n\n<p>Unused medicines and waste must be disposed of according to current instructions.<\/p>\n\n\n\n<p><strong>Dose<\/strong><\/p>\n\n\n\n<p>The doctor adapts the&nbsp;dose&nbsp;to you.<\/p>\n\n\n\n<p>The usual\u00a0dosage\u00a0is as follows:<\/p>\n\n\n\n<p><em><strong>To prevent re-infection with&nbsp;hepatitis&nbsp;B after liver transplantation due to liver failure caused by&nbsp;hepatitis&nbsp;B:<\/strong><\/em><\/p>\n\n\n\n<p><em>Adults<\/em><\/p>\n\n\n\n<p>The suggested&nbsp;dosage&nbsp;is 2160 IU&nbsp;intramuscularly&nbsp;every 15 days after transplantation, except for the first week.&nbsp;This&nbsp;dosage&nbsp;should be modified during long-term treatment to ensure an HBsAg antibody level above 100 IU\/l in HBV-&nbsp;DNA&nbsp;-negative patients and above 500 IU\/l in HBV-&nbsp;DNA&nbsp;-positive patients.<\/p>\n\n\n\n<p>Concomitant use of aa n appropriate antiviral agent (antiviral drug\u00a0)\u00a0should be considered as standard treatment to prevent the re-infection of hepatitis B.<\/p>\n\n\n\n<p><em><strong>Use in children<\/strong><\/em><\/p>\n\n\n\n<p>For the prevention of reinfection in children with&nbsp;hepatitis&nbsp;B after liver transplantation due to liver failure caused by&nbsp;hepatitis&nbsp;B, no data are available.<\/p>\n\n\n\n<p><em><strong>To prevent&nbsp;hepatitis&nbsp;B in the following cases:<\/strong><\/em><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li><em>Prevention\u00a0<\/em><em>of\u00a0hepatitis\u00a0B in non-immunized persons who have been inadvertently exposed to\u00a0hepatitis\u00a0B\u00a0virus<\/em>: at least 500 IU (international units), depending on the degree of exposure, as soon as possible after the exposure and preferably within 24-72 hours.<\/li><li>Prevention of\u00a0hepatitis\u00a0B in hemodialysis patients:8-12 IU\/kg but no more than 500 IU, every two months until the vaccination has become effective<\/li><li>Prevention of\u00a0hepatitis\u00a0B in newborn children of mothers who are carriers of the\u00a0hepatitis\u00a0B\u00a0virus<em>, at birth or as soon as possible after birth:<\/em>30-100 IU\/kg.\u00a0Repeated treatment with the drug may be required until the vaccination has become effective.<\/li><\/ul>\n\n\n\n<p>In all these situations vaccination against\u00a0hepatitis\u00a0B\u00a0virus\u00a0is strongly recommended.\u00a0The first vaccination dose can be injected on the same day as human immunoglobulin against\u00a0hepatitis\u00a0B but at different injection sites.<\/p>\n\n\n\n<p>If you have not shown&nbsp;an immune response&nbsp;(no measurable&nbsp;hepatitis&nbsp;B&nbsp;antibodies&nbsp;) after vaccination and if regular preventive treatment is necessary, doctors may consider injecting 500 IU (for adults) and 8 IU\/kg (for children) every two months.<a><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">If you have used too much Umanbig&nbsp;<\/h2>\n\n\n\n<p>The consequences of overdose are not known.<\/p>\n\n\n\n<p>If you have ingested too much medicine or if, for example,\u00a0a child has ingested the medicine by mistake, contact a doctor or hospital for an assessment of the risk and advice.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Possible side effects<\/h2>\n\n\n\n<p>Like all medicines, Umanbig can cause\u00a0side effects, although not everybthe ody gets them.<\/p>\n\n\n\n<p><strong>If you experience any of these\u00a0side effects, contact your doctor immediately or the nearest hospital:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Allergic reaction&nbsp;(hypersensitivity), anaphylactic&nbsp;shock&nbsp;(an extreme, often life-threatening&nbsp;allergic reaction&nbsp;).&nbsp;Symptoms of allergic reaction\/anaphylactic&nbsp;shock&nbsp;include&nbsp;itching&nbsp;, skin reactions, swelling of lips, face, tongue, difficulty swallowing, difficulty breathing, fainting.<\/li><\/ul>\n\n\n\n<p>The following\u00a0side effects\u00a0can generally occur after treatment with human immunoglobulins given intramuscularly:<br>&#8211;\u00a0side effects\u00a0such as chills, headache, dizziness, fever, vomiting, allergic reactions, nausea, joint pain (\u00a0arthralgia\u00a0), low\u00a0blood pressure,\u00a0and moderate pain in the lower back can sometimes occur ;<br>-in rare cases, human normal immunoglobulins can cause a sudden drop in blood pressure (\u00a0hypotension\u00a0) and, in rare cases, a\u00a0hypersensitivity reaction\u00a0(anaphylactic\u00a0shock\u00a0), even when the patient has not shown hypersensitivity during previous\u00a0administration\u00a0.<br>&#8211; local reactions at the injection site: pain, swelling,\u00a0redness\u00a0(\u00a0erythema\u00a0), induration, heat, rash,\u00a0itching\u00a0often occur.<\/p>\n\n\n\n<p>The following\u00a0sid effects\u00a0have been reported with the\u00a0adminand istration\u00a0of Umanbig during post-marketing use of theand  medicine (the frequency cannot be estimated from the available data).<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Headache<\/li><li>Increased heart rate (&nbsp;tachycardia&nbsp;)<\/li><li>Drop in blood pressure (&nbsp;hypotension&nbsp;)<\/li><li>Nausea<\/li><li>Vomiting<\/li><li>Skin reactions,&nbsp;redness&nbsp;(&nbsp;erythema&nbsp;),&nbsp;itching<\/li><li>Joint pain (&nbsp;arthralgia&nbsp;)<\/li><li>Fever<\/li><li>Feeling of illness<\/li><li>Overindulge<\/li><li>At the point of administration;&nbsp;pain, swelling, redness, induration, heat, rash,&nbsp;itching<\/li><\/ul>\n\n\n\n<p>For information about\u00a0virus\u00a0security, see section 2 \u201cWhat you fore using Umanbig\u201d<\/p>\n\n\n\n<p><strong>Other&nbsp;side effects&nbsp;in children<\/strong><\/p>\n\n\n\n<p>The frequency, type, and severity of\u00a0side effects\u00a0in childrenthe  are expected to be the same as in adults<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How Umanbig should be stored<\/h2>\n\n\n\n<p>Store out of sight and reach of children.<\/p>\n\n\n\n<p>Use before the eand xpiry date which is stated on the carton after the Expiration date.\u00a0and on the label after EXP.\u00a0The expiration date is the last day of the specified month.<\/p>\n\n\n\n<p>Store in a refrigerator (2&nbsp;<sup>o<\/sup>&nbsp;C-8&nbsp;<sup>o<\/sup>&nbsp;C).<\/p>\n\n\n\n<p>Store in the outer carton.&nbsp;Light sensitive.<\/p>\n\n\n\n<p>Do not freeze.<\/p>\n\n\n\n<p>Do not use Umanbig if the solution is cloudy or contains particles (\u00a0<em>see also &#8220;Appearance of the medicinal product and package sizes&#8221; under section 6 &#8220;Other information&#8221;<\/em>\u00a0).\u00a0Medicines must not be thrown into the drain or among the household waste.\u00a0Ask the pharmacist how to dispose of medications that are no longer used.\u00a0These measures will help to protect the environment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Contents of the packaging and other information<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Contents declaration<\/h2>\n\n\n\n<p>The active substance is human immunoglobulin against\u00a0hepatitis\u00a0B.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><thead><tr><th scope=\"col\"><\/th><th scope=\"col\">Umanbig 180 IU\/ 1 ml<\/th><th scope=\"col\">Umanbig 540 IU\/ 3 ml<\/th><\/tr><\/thead><tbody><tr><td>Human&nbsp;protein<\/td><td>100-180 g\/l<\/td><td>100-180 g\/l<\/td><\/tr><tr><td>of which human immunoglobulin G to at least<\/td><td>90%<\/td><td>90%<\/td><\/tr><tr><td>antibodies&nbsp;against HBs&nbsp;antigen&nbsp;(anti &#8211; HBs) at least<\/td><td>180 IU\/vial(180 IU\/ml)<\/td><td>540 IU\/vial(180 IU\/ml)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Distribution of IgG subclasses:<\/p>\n\n\n\n<p>IgG&nbsp;<sub>1<\/sub>&nbsp;63.7%<\/p>\n\n\n\n<p>IgG&nbsp;<sub>2<\/sub>&nbsp;31.8%<\/p>\n\n\n\n<p>IgG&nbsp;<sub>3<\/sub>&nbsp;3.3%<\/p>\n\n\n\n<p>IgG&nbsp;<sub>4<\/sub>&nbsp;1.2%<\/p>\n\n\n\n<p>The highest content of&nbsp;IgA&nbsp;is 300 micrograms\/ml.<\/p>\n\n\n\n<p>Made\u00a0from human\u00a0plasma.<\/p>\n\n\n\n<p>Other ingredients are\u00a0glycine, sodium chloride, and water for injections.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">ApInformationd package sizes of the medicine<\/h2>\n\n\n\n<p>Umanbig is a\u00a0solution for injection.<\/p>\n\n\n\n<p>The solution is clear and colorless or light yellow to light brown.&nbsp;During storage, the solution may become slightly cloudy or form small amounts of particles.<\/p>\n\n\n\n<p>Umanbig 180 IU\u00a0solution for injection:\u00a0vial\u00a0with 1 ml containing 180 IU.<\/p>\n\n\n\n<p>Umanbig 540 IU\u00a0solution for injection:\u00a0vial\u00a0with 3 ml containing 540 IU.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Marketing Authorisation Holder<\/h2>\n\n\n\n<p>Kedrion SpA &#8211; Loc.&nbsp;Ai Conti, 55051 Castelvecchio Pascoli, Barga (Lucca), Italy<\/p>\n\n\n\n<p><strong>Manufacturer<\/strong><\/p>\n\n\n\n<p>Kedrion SpA &#8211; SS 7 bis Km 19.5, S. Antimo (Napoli), Italy<\/p>\n\n\n\n<p><strong>This medicine is authorized in the Member States of the EEA under the following names:<\/strong><\/p>\n\n\n\n<p>Denmark: Uman Big<\/p>\n\n\n\n<p>Italy: UMAN BIG<\/p>\n\n\n\n<p>Poland: UMAN BIG<\/p>\n\n\n\n<p>Portugal: Uman Big<\/p>\n\n\n\n<p>Germany: UMAN BIG<\/p>\n\n\n\n<p>Hungary: Umanbig 180 IU\/ml oldatos injekci\u00f3<\/p>\n\n\n\n<p>Austria: UMAN BIG 180 IU\/ml Injektionsl\u00f6sung<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Umanbig is a solution of human immunoglobulin against\u00a0hepatitis\u00a0B. Immunoglobulins are blood proteins and act as\u00a0antibodies\u00a0.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":"","footnotes":""},"categories":[2200,22501],"tags":[],"class_list":["post-25998","post","type-post","status-publish","format-standard","hentry","category-medicines","category-u"],"_links":{"self":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/25998","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/comments?post=25998"}],"version-history":[{"count":3,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/25998\/revisions"}],"predecessor-version":[{"id":26031,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/25998\/revisions\/26031"}],"wp:attachment":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/media?parent=25998"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/categories?post=25998"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/tags?post=25998"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}